Discover
Instead of betting on one predefined biomarker, we use billions of aptamers to find disease-specific signatures directly from blood.
Each aptamer adopts a 3D shape that allows it to bind preferentially to specific molecular targets.
Aptamer discovery and AI find and refine each molecular signature. The signature is then detected: first as a laboratory-developed test in CLIA-certified labs, and next at the point-of-care on our graphene assay.
Aptamer discovery and AI are our upstream tools: they identify and refine the molecular signatures behind each test. Detection then branches into two routes. The first, and our first product, is a laboratory-developed test run in CLIA-certified laboratories. The second, the one we are building toward, is a graphene assay that brings the same signature to the point-of-care.
Instead of betting on one predefined biomarker, we use billions of aptamers to find disease-specific signatures directly from blood.
AI learns the complex molecular patterns that predict diagnosis, treatment response and disease progression.
Our first route to patients: the signature, measured in CLIA-certified laboratories as a laboratory-developed test (LDT).
Where we're heading: the same signatures, detected directly from a blood sample by a graphene assay at the point-of-care.
We received the report from the first batch of samples in our multicenter European study. The results exceeded our expectations. Then the Montréal cohort reproduced them.
Today the right psychiatric treatment is found by elimination, one failed prescription at a time. An objective blood test changes where that search starts.
Every failed treatment is months a patient spends on the wrong medication. We're built to take that time back.